Phase IIb Clinical Trial With TGF-β2 Antisense Compound AP 12009 for Recurrent or Refractory High-grade Glioma
Status:
Completed
Trial end date:
2009-03-01
Target enrollment:
Participant gender:
Summary
In this multinational dose finding Phase IIb study the efficacy and safety of two doses of AP
12009 compared to standard chemotherapy (temozolomide or PCV) is investigated in adult
patients with confirmed recurrent high-grade glioma.